Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-06-27

AUTHORS

Norbert Gattermann

ABSTRACT

Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy. More... »

PAGES

24-29

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z

DOI

http://dx.doi.org/10.1007/s12185-008-0118-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010032558

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18581200


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Education, Medical, Continuing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Chelating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Overload", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Societies, Medical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfusion Reaction", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008-06-27", 
    "datePublishedReg": "2008-06-27", 
    "description": "Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-008-0118-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "88"
      }
    ], 
    "keywords": [
      "iron chelation therapy", 
      "transfusional iron overload", 
      "myelodysplastic syndrome", 
      "iron overload", 
      "chelation therapy", 
      "red blood cell transfusion", 
      "lower-risk myelodysplastic syndromes", 
      "National Comprehensive Cancer Network", 
      "blood cell transfusion", 
      "Comprehensive Cancer Network", 
      "MDS Foundation", 
      "cell transfusion", 
      "symptomatic anemia", 
      "guideline group", 
      "consensus statement", 
      "Cancer Network", 
      "healthcare professionals", 
      "therapy", 
      "patients", 
      "overview of guidelines", 
      "Italian Society", 
      "transfusion", 
      "ongoing management", 
      "syndrome", 
      "overload", 
      "guidelines", 
      "group", 
      "anemia", 
      "hematology", 
      "management", 
      "treatment", 
      "professionals", 
      "recommendations", 
      "strategies", 
      "number", 
      "overview", 
      "statements", 
      "region", 
      "society", 
      "approach", 
      "world", 
      "foundation", 
      "network"
    ], 
    "name": "Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload", 
    "pagination": "24-29", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010032558"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-008-0118-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18581200"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-008-0118-z", 
      "https://app.dimensions.ai/details/publication/pub.1010032558"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_455.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-008-0118-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      20 PREDICATES      77 URIs      69 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-008-0118-z schema:about N01dd8de5bd184d1b99e06aa3e7da51b5
2 N57823c22c29f486096b18595ece762f1
3 N5901808a25d24c6ab1a41a00e14a962b
4 N5c3994a37dad4621971f15dd02683d10
5 N9bade7d5af1e4c78a8048d9f382f90d9
6 Na7fa702d286b466fa1cb9b0d595fb0c1
7 Nb90aa49d6f394e8883f942962b4e792a
8 Ncdf8b2dfbc4148ab83ee1ceb3722934d
9 Nd6bd4e68bcea4b6d9fae79ca193dfc3b
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author N521dc8315d0a4c4089e67da7f4af0423
13 schema:datePublished 2008-06-27
14 schema:datePublishedReg 2008-06-27
15 schema:description Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy.
16 schema:genre article
17 schema:isAccessibleForFree true
18 schema:isPartOf N492cb10fbdfc44aa9fe9601dcacf434a
19 Nc984a7e6037d4a84b491a2294df5de5b
20 sg:journal.1076985
21 schema:keywords Cancer Network
22 Comprehensive Cancer Network
23 Italian Society
24 MDS Foundation
25 National Comprehensive Cancer Network
26 anemia
27 approach
28 blood cell transfusion
29 cell transfusion
30 chelation therapy
31 consensus statement
32 foundation
33 group
34 guideline group
35 guidelines
36 healthcare professionals
37 hematology
38 iron chelation therapy
39 iron overload
40 lower-risk myelodysplastic syndromes
41 management
42 myelodysplastic syndrome
43 network
44 number
45 ongoing management
46 overload
47 overview
48 overview of guidelines
49 patients
50 professionals
51 recommendations
52 red blood cell transfusion
53 region
54 society
55 statements
56 strategies
57 symptomatic anemia
58 syndrome
59 therapy
60 transfusion
61 transfusional iron overload
62 treatment
63 world
64 schema:name Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
65 schema:pagination 24-29
66 schema:productId N224d225c53e24b2987f43abaf8445588
67 N6aab895b72fb4fd1896a8ad92efe651f
68 Naaa691da948949b9a6c04ed8655bc50f
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010032558
70 https://doi.org/10.1007/s12185-008-0118-z
71 schema:sdDatePublished 2022-08-04T16:57
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher Nef56c1e558d649f2bab412ab945e641f
74 schema:url https://doi.org/10.1007/s12185-008-0118-z
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N01dd8de5bd184d1b99e06aa3e7da51b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Iron Chelating Agents
80 rdf:type schema:DefinedTerm
81 N224d225c53e24b2987f43abaf8445588 schema:name doi
82 schema:value 10.1007/s12185-008-0118-z
83 rdf:type schema:PropertyValue
84 N492cb10fbdfc44aa9fe9601dcacf434a schema:issueNumber 1
85 rdf:type schema:PublicationIssue
86 N521dc8315d0a4c4089e67da7f4af0423 rdf:first sg:person.01273447501.34
87 rdf:rest rdf:nil
88 N57823c22c29f486096b18595ece762f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Societies, Medical
90 rdf:type schema:DefinedTerm
91 N5901808a25d24c6ab1a41a00e14a962b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Blood Transfusion
93 rdf:type schema:DefinedTerm
94 N5c3994a37dad4621971f15dd02683d10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Myelodysplastic Syndromes
96 rdf:type schema:DefinedTerm
97 N6aab895b72fb4fd1896a8ad92efe651f schema:name pubmed_id
98 schema:value 18581200
99 rdf:type schema:PropertyValue
100 N9bade7d5af1e4c78a8048d9f382f90d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 Na7fa702d286b466fa1cb9b0d595fb0c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Practice Guidelines as Topic
105 rdf:type schema:DefinedTerm
106 Naaa691da948949b9a6c04ed8655bc50f schema:name dimensions_id
107 schema:value pub.1010032558
108 rdf:type schema:PropertyValue
109 Nb90aa49d6f394e8883f942962b4e792a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Iron Overload
111 rdf:type schema:DefinedTerm
112 Nc984a7e6037d4a84b491a2294df5de5b schema:volumeNumber 88
113 rdf:type schema:PublicationVolume
114 Ncdf8b2dfbc4148ab83ee1ceb3722934d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Transfusion Reaction
116 rdf:type schema:DefinedTerm
117 Nd6bd4e68bcea4b6d9fae79ca193dfc3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Education, Medical, Continuing
119 rdf:type schema:DefinedTerm
120 Nef56c1e558d649f2bab412ab945e641f schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
126 schema:name Cardiorespiratory Medicine and Haematology
127 rdf:type schema:DefinedTerm
128 sg:journal.1076985 schema:issn 0925-5710
129 1865-3774
130 schema:name International Journal of Hematology
131 schema:publisher Springer Nature
132 rdf:type schema:Periodical
133 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
134 schema:familyName Gattermann
135 schema:givenName Norbert
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
137 rdf:type schema:Person
138 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany
139 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...